Last reviewed 2026-04-20 · How we verify

PERAMIVIR ANHYDROUS

FDA-approved approved Small molecule Quality 0/100

PERAMIVIR ANHYDROUS is a drug. It is currently FDA-approved (first approved 2014).

Peramivir Anhydrous is a marketed antiviral drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and patent protection, providing a competitive edge over generic alternatives. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	PERAMIVIR ANHYDROUS
Modality	Small molecule
Phase	FDA-approved
First approval	2014

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PERAMIVIR ANHYDROUS CI brief — competitive landscape report
PERAMIVIR ANHYDROUS updates RSS · CI watch RSS

Frequently asked questions about PERAMIVIR ANHYDROUS

What is PERAMIVIR ANHYDROUS?

PERAMIVIR ANHYDROUS is a Small molecule drug.

When was PERAMIVIR ANHYDROUS approved?

PERAMIVIR ANHYDROUS was first approved on 2014.

What development phase is PERAMIVIR ANHYDROUS in?

PERAMIVIR ANHYDROUS is FDA-approved (marketed).

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing